Vertex Pharma scientist talks about the long road to developing non
WASHINGTON (AP) — For decades, patients seeking medication for pain have had two choices: over-the-counter drugs like aspirin or powerful prescription opioids like oxycodone.
Opioid prescriptions have plummeted over the last decade as doctors have become more attuned to the risks of addiction and misuse during the country’s ongoing drug epidemic.
Vertex Pharmaceuticals recently reported positive results for a non-opioid painkiller, one of several medications the Boston-based drugmaker has been developing for various forms of pain. Patients taking the drug after surgery experienced more pain relief than those getting a placebo, although the drug didn’t meet a secondary goal of outperforming treatment with an opioid.
The Associated Press spoke with Vertex’s chief scientist Dr. David Altshuler about the company’s research and development plans. The interview has been edited for length and clarity.
Related articles
Kristin Cavallari, 37, ignores critics of her age
Kristin Cavallari is enjoying a romantic rendezvous with her much younger cowboy lover Mark Estes in2024-05-22European Sand Sculpture Championships held in Zandvoort, the Netherlands
An artist works on a sand sculpture during the European Sand Sculpture Championships in Zandvoort, t2024-05-22Late night shooting in Philadelphia leaves at least three dead, 11 injured
Candles are lit during a vigil to mourn for victims of a school mass shooting at Town Square in Uval2024-05-22German dependency on Russian energy significantly reduced: president
German President Frank-Walter Steinmeyer attends a news conference at Cotroceni Presidential Palace2024-05-22Padres second baseman Xander Bogaerts leaves game against Braves with shoulder injury
ATLANTA (AP) — San Diego Padres second baseman Xander Bogaerts injured his left shoulder and was rem2024-05-22World political party leaders hail CPC's people
Cyril Ramaphosa, president of the African National Congress and South African president, addresses t2024-05-22
atest comment